These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30248217)

  • 1. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
    Young G; Collins PW; Colberg T; Chuansumrit A; Hanabusa H; Lentz SR; Mahlangu J; Mauser-Bunschoten EP; Négrier C; Oldenburg J; Patiroglu T; Santagostino E; Tehranchi R; Zak M; Karim FA
    Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
    Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
    Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
    Negrier C; Young G; Abdul Karim F; Collins PW; Hanabusa H; Colberg T; Goldman B; Walsh CE;
    Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonacog Beta Pegol: A Review in Haemophilia B.
    Syed YY
    Drugs; 2017 Dec; 77(18):2003-2012. PubMed ID: 29124682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
    Chan AK; Alamelu J; Barnes C; Chuansumrit A; Garly ML; Meldgaard RM; Young G
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1101-1113. PubMed ID: 33134776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.
    Sørensen MH; Andersen S; Ezban M
    Haemophilia; 2015 Nov; 21(6):832-6. PubMed ID: 25929807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
    Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
    J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
    Collins PW; Young G; Knobe K; Karim FA; Angchaisuksiri P; Banner C; Gürsel T; Mahlangu J; Matsushita T; Mauser-Bunschoten EP; Oldenburg J; Walsh CE; Negrier C;
    Blood; 2014 Dec; 124(26):3880-6. PubMed ID: 25261199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years.
    Walsh KS; Mrakotsky C; Carcao M; Chan AKC; Nielsen PH; Holst H; Shapiro K
    Res Pract Thromb Haemost; 2024 Feb; 8(2):102341. PubMed ID: 38516633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
    Iorio A; MacDonald V; Caillaud A; Luckevich MD; Christoffersen P; Matino D; Keepanasseril A; Iserman E; Germini F; Bentley A; Poon MC
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100106. PubMed ID: 37065846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
    Powell J; Shapiro A; Ragni M; Negrier C; Windyga J; Ozelo M; Pasi J; Baker R; Potts J; Li S; Mei B; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):113-23. PubMed ID: 25209873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
    Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
    Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.